PharmaCyte Biotech (PharmaCyte Biotech) Growth Rank : 0 (As of May. 18, 2024)

View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech Growth Rank?

PharmaCyte Biotech has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

PharmaCyte Biotech Growth Rank Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

PharmaCyte Biotech (PharmaCyte Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169

Website

https://www.pharmacyte.com

PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. It is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.

Executives

Wayne Remell Walker	director	1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein	director	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover	director	C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb	director	100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen	director	299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr	director	3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K	director
Carlos Trujillo	director, officer: CFO	8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner	director, officer: Chairman, CEO, Pres and GC	8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree	director, officer: Chief Science Officer	12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis	director	C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099